Proactive Investors - Run By Investors For Investors

Allergy Therapeutics completes recruitment for phase III birch pollen trial

Results from study of PQ Birch are expected in the second half of this year
woman sneezing
Work will get underway during the birch pollen season

Allergy Therapeutics plc (LON:AGY) has completed the recruitment to a European phase III clinical trial of its ultra-short course treatment for people allergic to birch pollen.

Results from study of PQ Birch are expected in the second half of this year. Researchers will assess the efficacy of the aluminium-free inoculation alongside the safety of the injection.

READ: Allergy Therapeutics teams up with Ergomed to take its anti-allergy tablets through the clinic

A total of 560 people from 59 different centres in Germany, Austria, Poland and Sweden are taking part in the trial, which will get underway during birch pollen season.

Success would pave the way for marketing authorisation. Chief executive Manuel Llobet said the successful development of PQ Birch would “strengthen the group's portfolio and help address the current unmet needs”.

READ: Allergy Therapeutics - strong financial showing, solid cash position, progress in the clinic

The product is one of a number of ultra-short course, injected immunotherapy products in clinical development for various allergies, which are part of Allergy Therapeutics’ three-pillar strategy. The company is investing heavily from its growing revenue stream in its pipeline as well as expanding its base in Europe, while preparing for entry to the US.

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

1534940807_rsz_shutterstock_130327115.jpg
August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
cough
October 19 2018
Respiratory syncytial virus causes the common cold, for which there is no effective cure.
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use